As employers grapple with the soaring demand for glucagon-like peptide-1 (GLP-1) medications, Eric Levin, CEO and cofounder ...

After a median follow-up of 13.3 months (95% CI, 9.04-18.69), the median duration of response was 18.1 months, progression ...

Richter transformation develops in 2%–10% of CLL cases, often with rapid clinical decline, limited chemotherapy efficacy, and ...

Personal factors explained significant variance in five of six participation outcomes (R² 13%–48%), while environmental factors added ~11% for satisfaction and ~11% for GPS-based activity. Perceived ...

Among patients with steatotic liver disease (SLD), patients with alcohol-associated liver disease (ALD) carry the highest risk of cirrhosis, followed by those with metabolic dysfunction–associated ...

Clinical measures and biomarkers during pregnancy, including hs-cTnI and sFlt-1, can help identify women at higher risk of developing cardiovascular disease later in life.

Elona Toska, MSc, DPhil, explores drivers of HIV in pregnant women and young mothers: biology, relationships, and postpartum ...

Noel T. Brewer, PhD, former ACIP member, warns that the CDC's reduction from 17 to 11 recommended immunizations lacks ...

Patients taking ACE inhibitors and ARBs saw a 16% reduction in their risk of cancer progression (HR, 0.84; 95% CI, 0.71-0.99; ...

Rural cardiovascular disparities and limited specialist access are motivating AI decision-support adoption to help determine ...

In this episode, Overcoming Access Barriers and Step-Edit Challenges in IgA Nephropathy Care, the panelists explore the ...

ACOs entering MSSP with higher spending were consistently more likely to earn bonuses—a gap that persisted after a 2017 ...